The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:863-864 August 21, 2008 Number 8
NextNext

Human Papillomavirus Vaccine in Males

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: In 2006, the Food and Drug Administration (FDA) licensed the human papillomavirus (HPV) vaccine for use in females 9 to 26 years old. The vaccine helps prevent cervical cancer, precancerous genital lesions, and genital warts. Trials of the vaccine in males are currently under way. If these trials demonstrate protection against HPV for males and if the FDA licenses the vaccine, should we promote its use in males?

HPV infection is the most common sexually transmitted illness in young people — those who are 15 to 24 years old. It is estimated that in 2000 there were . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.